期刊文献+

伐昔洛韦联合咪喹莫特乳膏预防频发性生殖器疱疹复发的疗效观察 被引量:8

Effects of valacyclovir and imiquimod cream on recurrent genital herpes
下载PDF
导出
摘要 目的:探讨伐昔洛韦联合咪喹莫特乳膏对预防频发性生殖器疱疹复发的疗效及安全性。方法:将2009年至2012年东莞市太平人民医院收治的102例频发性生殖器疱疹患者分为治疗组(52例)和对照组(50例)。两组均口服伐昔洛韦片450 mg,每日2次;治疗组加用咪喹莫特乳膏外用,每周3次;疗程均为3个月。观察两组患者治愈率、有效率和复发率。结果:治疗组痊愈率、总有效率略高于对照组,但差异无统计学意义(x^2=0.812,P>0.05)。治疗组总复发率(36.5%)低于对照组总复发率(82.0%),两组比较,差异有统计学意义(x^2=9.781,P<0.05)。两组治疗期间均未发生严重不良反应。结论:伐昔洛韦联合咪喹莫特乳膏比单用伐昔洛韦更能减低频发性生殖器疱疹的复发率,值得临床推广。 Objective: To investigate the efficacy and safety of valacyclovir and imiquimod cream for the treatment of recurrent genital herpes. Methods : Bet-seen 20039 and 2012, we allocated 102 patients with reeurrent genital herpes who were admitted to Taiping People' s Hospital of Dongguan to be treated with valacyclovir 450 mg twice daily alone (control group, n = 50) or in combination with topical imiquimod cream thrice weekly for 3 months (treatment group, n = 52 ). This entailed the comparison on the cure, effective and relapse rates. Results: The treatment group yielded numerically but not statistically higher cure and total effective rates than control group (both P 〉 0.05 ). However, treatment group was associated with a markedly lower rate of relapse (36.5% vs. 82%, χ2= 9. 781, P 〈 0.05 ) compared with control group. No serious adverse events were reported during the treatment. Conclusion : The combination of valacyclovir and imiquimod cream, compared with valacyclovir alone, is more and effective and safer for the treatment of recurrent genital herpes.
出处 《广州医学院学报》 2013年第6期58-59,共2页 Academic Journal of Guangzhou Medical College
关键词 频发性生殖器疱疹 伐昔洛韦 咪喹莫特 recurrent genital herpes valacyclovir imiquimod
  • 相关文献

参考文献7

二级参考文献92

  • 1顾恒,曾凡钦,郭在培,彭振辉,毕志刚,朱学骏,陈昆,郭庆,张谊之,闫乎铃,张美华,韩钢文,常宝珠,刘训荃(指导),王家璧(指导).咪喹莫特乳膏治疗尖锐湿疣随机、双盲、多中心研究[J].中华皮肤科杂志,2003,36(9):501-504. 被引量:96
  • 2[1]Stephen K,Tyring,Istvan A,et al.a radomized,controlled molecular study of condylomata acuminate clearance during treatment with imiquimod[ J].J Infect Dis 1998;178:551.
  • 3[2]Stanley MA.Mechanism of action of imiquimod[ J ].Papillomavirus Report,1999;10(2):23.
  • 4[3]Miller RL,Gerster JF,Owens ML,et al.Imiquimod applied topically:a novel immune response modifier and new class of drug[J].Intern J Immunopharm,1999;21:1.
  • 5[4]Edwards L,Ferenczy A,Eron L,et al.Self-administered topical 5% imiquimod cream for external anogenital warts[J].Arch Dermatol,1998; 134:25.
  • 6[5]Edwards L,Imiquimod in clinical practice[J].J Am Acad Dermatol,2000 ;43:S12.
  • 7[6]Vilata J J,Sierra X.Efficacy of imiquimod 5% cream in treating genital and perianal warts.
  • 8[7]Beutner KR,Tyring SK,Trfaffer Jr JKF,et al.Imiguimod,a patient-applied immune-respose modifier for treatment of external genital warts[J].Antimicrob Agents Chenother,1998;42:789.
  • 9[8]Beutner KR,Spruance SL Hongharm AJ,et al.Treatment of genital warts with an immane -response modifer (Imiquimod)[J].JAmAcadDermatol,1998;38(PtI):230.
  • 10[9]Garland SM,Sellors JW,Wikstrom A,et al.Imiquimod 5%cream is a safe and effective self-applied treatment for anogenictal warts-results of an open-label,multicentre phate Ⅲ B Trial[J].InterJSTD&AIDS,2001 ;12:722.

共引文献79

同被引文献70

  • 1卞晓洁,勉强辉,丁黎,杨林,文爱东.人血浆中阿昔洛韦的HPLC-MS法的建立及盐酸伐昔洛韦片的生物等效性研究[J].药学与临床研究,2007,15(1):28-32. 被引量:9
  • 2木尼热.阿布都克热木,王楠楠,唐玉海,木合塔尔.吐尔洪.流动注射-化学发光法测定阿昔洛韦和更昔洛韦[J].西安交通大学学报(医学版),2007,28(6):707-710. 被引量:7
  • 3Chuluunbaatar U, Mohr I. A herpesvirus kinase that masquerades as Akt : you don' t have to look like Akt, to act like it. Cell cycle,2011, 10(13) :2064 -2068.
  • 4DENG Yunhua,YANG Dougliang, CHEN Xingping, et al. Tcl/Tc2 Imbalance in the Peripheral Blood of Patients with Recurrent Genital Herpes. Journal of Huazhong University of Science and Technology, 2006,26( 1 ) : 145 - 147.
  • 5El - Gehary A, Bukhari FA. Optimal stabilization of steady - states of the genital herpes epidemic during infinite and finite time intervals. Applied Mathematics and Computation ,2003,137 ( 1 ) :33 - 47.
  • 6Bonnar PE.Suppressive valaeyclovir therapy to reduce genital herpes transmission:good public health policy.Megill J Med,2009,12(1):39-46.
  • 7Schiffer JT,Corey L.New concepts in understanding genital herpes.Curr Infect Dis Rep,2009,11(6):457-464.
  • 8Gill N,Davies EJ,Ashkar AA.The role of toll-like receptorligands/agonists in protection against genital HSV-2 infection.Am J Reprod Immunol,2008,59(1):35-43.
  • 9Welner RS,Pelayo R,Naqai Y.Lymphoid precursors aredirected to produce dendritic cells as a result of TLR9 ligationduring herpes infection.Blood,2008,112(9):3753-3761.
  • 10Zervoudis S,Iatrakis G,Peitsidis P,et al.Complementary treatment with oral Pidotimod plus vitamin C after laser vaporization for female genital warts:a prospective study.J Med Life,2010,3(3):286.

引证文献8

二级引证文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部